Related Experiment Video
Updated: Aug 10, 2026

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice
Published on: September 17, 2015
Pharmacokinetics of multiple doses of valsartan in patients with heart failure
Pratapa P Prasad1, Ching-Ming Yeh, Peter Gurrieri
1Novartis Pharmaceuticals Corp., Clinical Pharmacology, East Hanover, NJ 07936, USA. pratapa.prasad@pharma.novartis.com
Abstract:
Angiotensin II has adverse actions in heart failure including vasoconstriction, aldosterone secretion, and activation of the sympathetic nervous system. Valsartan, a potent specific angiotensin II type 1 receptor blocker, may produce beneficial effects in heart failure. The purpose of this study was to evaluate the steady-state pharmacokinetics of valsartan 40, 80, and 160 mg each given every 12 h for 7 days in heart failure patients. Eighteen patients with chronic stable heart failure and left ventricular ejection fractions
Related Concept Videos
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Bioavailability Study Design: Single Versus Multiple Dose Studies
Dosage Regimen: Multiple Oral Dosage
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
